Transfer of Human Material. (a) The Parties will ensure that each Research Project is approved by NCI, the Recipient CIMAC(s), and the CIDC before the transfer of any Human Material from the Provider to the Recipient CIMAC(s). NCI approval includes the requirement of review of any agreements between or among Provider and NCI/Pharma Collaborator(s) related to the Human Material, to ensure the terms comply with the CIMAC-CIDC Guidelines and with this Agreement.
Transfer of Human Material. The Parties will ensure that each Research Project is approved by NCI before the transfer of any Human Material from the Provider. NCI approval includes the requirement of review of any agreements between Provider and Pharma Collaborator related to the Human Material, to ensure the terms comply with the CIMAC-CIDC Guidelines. If approved under the Research Project and covered by this Agreement or another CIMAC-CIDC HMTA, the Human Material may be transferred by the Provider to the CIMACs specified in the relevant agreement(s) under a LoT. Provider will ensure that NCI receives a copy of each LoT. Biospecimens that are transferred from the Provider to a Recipient will not be redistributed from that Recipient CIMAC to another non-recipient CIMAC unless approved in writing by NCI. Transfer of the Human Material outside of the CIMAC-CIDC will require the prior written permission of the Provider and, for NCI-supported Protocols, NCI, as well as an appropriate transfer agreement between the CIMAC-CIDC and the non-CIMAC-CIDC recipient that contains restrictions and obligations that are consistent with this Agreement. Provider is responsible for transferring the CLIA form concurrently with the Biospecimens if a CLIA assay is going to be performed on the Biospecimens. Provider will transfer the Specimen Tracking Manifest to Recipients as directed by NCI concurrently with the transfer of the Biospecimens.
Transfer of Human Material. The Parties will ensure that each Research Project is approved by NCI, the Recipient CIMAC(s), and the CIDC before the transfer of any Human Material from the Provider to the Recipient CIMAC(s). NCI approval includes the requirement of review of any agreements between or among Provider and NCI/Pharma Collaborator(s) related to the Human Material, to ensure the terms comply with the CIMAC-CIDC Guidelines and with this Agreement. Biospecimens that are transferred from the Provider to a Recipient CIMAC will not be redistributed from such Recipient CIMAC to another CIMAC (regardless of whether such CIMAC is a Recipient CIMAC or otherwise) unless approved in writing by NCI. The Provider shall retain title to Biospecimens. Transfer of the Human Material outside of the CIMAC-CIDC will require the prior written permission of the Provider and, for NCI-supported Protocols, NCI, as well as an appropriate transfer agreement between the CIMAC-CIDC and the non-CIMAC-CIDC recipient that contains restrictions and obligations that are consistent with this Agreement. Provider is responsible for transferring the CLIA form concurrently with the Biospecimens if a CLIA assay is going to be performed on the Biospecimens. Provider will transfer the Specimen Tracking Manifest to Recipient CIMACs and CIDC as directed by NCI concurrently with the transfer of the Biospecimens. Biospecimens may be provided directly by Provider, a CIMAC, or through the NCI biobank on the CIMAC’s behalf to an outside vendor for use of its services, as applicable to the Research Project and in accordance with the Master Services Agreements between NCI and the vendors for CIMAC-CIDC studies. Use of Human Material. Recipients will ensure that the Human Material will only be used in accordance with the NCI-approved Research Project as specified in the Exhibits. For clarity, other than the Clinical Data that are contained in the Specimen Tracking Manifest, the CIMACs will access the Clinical Data only through the CIDC. Recipients will ensure that Human Material will only be used in compliance with all applicable laws and regulations concerning the use of Biospecimens and Clinical Data, including, as applicable, IRB approval and institutional certification. Recipients agree to comply with the terms of the CTEP IP Option as it relates to the provision of rights to NCI/Pharma Collaborators to data and inventions generated from the use of the Human Material. Notwithstanding anything to the contrary in this Agree...
